GlobeImmune, Inc: GlobeImmune Announces Completion of $7.5 Million Private Placement

  GlobeImmune, Inc: GlobeImmune Announces Completion of $7.5 Million Private
                                  Placement

LOUISVILLE, Colo., Feb. 13, 2014 - GlobeImmune, Inc., today announced that  on 
February 11, 2014, the company completed  a $7.5 million private placement  of 
convertible notes and warrants. The notes accrue interest and will be settled
in cash or stock under various scenarios. Proceeds from the private placement
are to be used for  general corporate purposes. SternAegis Ventures,  through 
Aegis Capital Corp., acted as the placement agent for the offering.

GlobeImmune is focused on advancing  multiple clinical programs in  infectious 
disease and oncology. Ongoing studies of Tarmogen product candidates include a
Phase 2 trial  of GS-4774 for  chronic hepatitis B  being conducted by  Gilead 
Sciences, Inc.  under the  company's license  agreement, a  Phase 2  trial  of 
GI-6207 in patients with metastatic  medullary thyroid cancer being  conducted 
at the National Cancer  Institute (NCI), and GI-6301  being developed under  a 
license with Celgene Corporation.

This press release does not constitute an offer to sell or the solicitation of
an offer to buy securities, nor shall there be any sale of these securities in
any jurisdiction in which such offer,  solicitation or sale would be  unlawful 
prior to the registration  or qualification under the  securities laws of  any 
such jurisdiction.

About GlobeImmune

GlobeImmune is a biopharmaceutical company focused on developing products  for 
the treatment of infectious disease and and oncology based on its  proprietary 
Tarmogen platform. Tarmogens  are believed  to activate the  immune system  by 
stimulating cellular  immunity,  known as  T  cell immunity,  in  contrast  to 
traditional vaccines  that predominately  stimulate antibody  production.  To 
date, Tarmogen  product  candidates  have been  generally  well  tolerated  in 
clinical  trials  for  multiple  disease  indications  and  are  efficient  to 
manufacture. In May 2009, the company entered into a collaboration  agreement 
with  Celgene   Corporation  focused   on  the   discovery,  development   and 
commercialization of  product  candidates for  the  treatment of  cancer.  In 
October 2011, the  company entered into  a worldwide, strategic  collaboration 
with Gilead Sciences, Inc., to develop Tarmogens for the treatment of  chronic 
hepatitis B infection. For additional information, please visit the  company's 
website at www.globeimmune.com.

                                     ###

GlobeImmune Contact:
Timothy C. Rodell M.D.
President & Chief Executive Officer
T: 303-625-2800
information@globeimmune.com

INVESTOR CONTACT:
Susan Noonan
S.A. Noonan Communications, LLC
T: 212-966-3650
susan@sanoonan.com

Media Contacts:
Lena Evans or Tony Russo, Ph.D.
Russo Partners, LLC
T: 212-845-4262 or 212-845-4251
lena.evans@russopartnersllc.com
tony.russo@russopartnersllc.com

------------------------------------------------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf
of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for
the content, accuracy and originality of the information contained therein.
Source: GlobeImmune, Inc via Globenewswire
HUG#1761581
 
Press spacebar to pause and continue. Press esc to stop.